Skip to main content

Advertisement

SpringerLink
Log in

Systemic lupus erythematosus: a therapeutic challenge for the XXI century

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Despite significant advances in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), there are only a few drugs approved by the regulatory agencies across the world for the treatment of these patients; in fact, many of the compounds subjected to clinical trials have failed in achieving their primary endpoints. Current therapeutic options include antimalarials which should be used in all SLE patients unless they are strongly contraindicated, glucocorticoids which should be used at the lowest possible dose and for the shortest possible time, and immunosuppressive drugs which should be used judiciously, mainly in patients with severe organ involvements or receiving high doses of steroids to control their disease. Despite improvement on the survival of SLE patients, damage accrual has not varied over the last few decades, reflecting a gap between these therapeutic options and the expectations of these patients and their treating physicians. Biologic compounds can be used in some refractory cases. However, their cost is of great concern for both the patients and the health system. Cost is of special importance in low-income countries, because low-income SLE patients tend to experience a more severe disease having an overall worse prognosis which is compounded by their limited access to the health system. Although a treatment to target based on defined molecular pathways for specific disease subsets is appealing, this is not yet a reality. This review addressed current therapeutic options for SLE patients and the state of the art of investigational drugs targeting pathogenic pathways identified in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME (2004) Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 3(6):423–453

    Article  PubMed  Google Scholar 

  2. Kasitanon N, Magder LS, Petri M (2006) Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85(3):147–156

    Article  Google Scholar 

  3. Alarcon GS, Bastian HM, Beasley TM, Roseman JM, Tan FK, Fessler BJ, Vila LM, McGwin G Jr (2006) Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement. Lupus 15(1):26–31

    Article  PubMed  CAS  Google Scholar 

  4. Alarcon GS, Roseman J, Bartolucci AA, Friedman AW, Moulds JM, Goel N, Straaton KV, Reveille JD (1998) Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 41(7):1173–1180

    Article  PubMed  CAS  Google Scholar 

  5. Duran S, Apte M, Alarcon GS (2007) Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J Natl Med Assoc 99(10):1196–1198

    PubMed Central  PubMed  Google Scholar 

  6. Sanchez ML, McGwin G Jr, Duran S, Fernandez M, Reveille JD, Vila LM, Alarcon GS (2009) Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D. Clin Exp Rheumatol 27(1):67–71

    PubMed  CAS  Google Scholar 

  7. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20(5):1103–1112

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  8. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28

    Article  PubMed  CAS  Google Scholar 

  9. Ruiz-Irastorza G, Danza A, Khamashta M (2012) Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 51(7):1145–1153

    Article  CAS  Google Scholar 

  10. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, Fuentes de la Mata J, Clark P, Vargas F, Alocer-Varela J (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64(4):620–625

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Petri M (2004) Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13(5):366–371

    Article  PubMed  CAS  Google Scholar 

  12. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125(7):549–557

    Article  PubMed  CAS  Google Scholar 

  13. Yildirim-Toruner C, Diamond B (2011) Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127(2):303–312

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS (2011) Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 38(1):69–78

    Article  PubMed  CAS  Google Scholar 

  15. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49(1):128–140

    Article  Google Scholar 

  16. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365(20):1886–1895

    Article  PubMed  CAS  Google Scholar 

  17. Ginzler E, Sharon E, Diamond H, Kaplan D (1975) Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 18(1):27–34

    Article  PubMed  CAS  Google Scholar 

  18. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350(10):971–980

    Article  PubMed  CAS  Google Scholar 

  19. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59(12):1796–1804

    Article  PubMed  CAS  Google Scholar 

  20. Carneiro JR, Sato EI (1999) Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 26(6):1275–1279

    PubMed  CAS  Google Scholar 

  21. Moroni G, Doria A, Ponticelli C (2009) Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 24(1):15–20

    Article  PubMed  CAS  Google Scholar 

  22. Ogawa H, Kameda H, Amano K, Takeuchi T (2010) Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 19(2):162–169

    Article  PubMed  CAS  Google Scholar 

  23. Deng J, Huo D, Wu Q, Yang Z, Liao Y (2012) A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med 227(4):281–288

    Article  PubMed  CAS  Google Scholar 

  24. Chen W, Liu Q, Tang X, Fu P, Liu F, Liao Y, Yang Z, Zhang J, Chen J, Lou T, Fu J, Kong Y, Liu Z, Li Z, Yu X (2012) Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21(9):944–952

    Article  PubMed  CAS  Google Scholar 

  25. Lanata CM, Mahmood T, Fine DM, Petri M (2010) Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 19(8):935–940

    Article  PubMed  CAS  Google Scholar 

  26. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13(8):601–604

    Article  PubMed  CAS  Google Scholar 

  27. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17(7):638–644

    Article  PubMed  CAS  Google Scholar 

  28. Wu GC, Xu XD, Huang Q, Wu H (2013) Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 33(2):273–276

    Article  PubMed  CAS  Google Scholar 

  29. Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta JA (2013) Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res. doi:10.1002/acr.22173

  30. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT (2008) Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 35(11):2152–2158

    Article  PubMed  Google Scholar 

  31. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71(11):1833–1838

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  32. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harle JR, Hot A, Kahn JE, Lambotte O, Larroche C, Leone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 62(8):2458–2466

    Article  PubMed  CAS  Google Scholar 

  33. Narvaez J, Rios–Rodriguez V, de la Fuente D, Estrada P, Lopez-Vives L, Gomez-Vaquero C, Nolla JM (2011) Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 41(3):364

    Article  PubMed  CAS  Google Scholar 

  34. Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, Garcia-Hernandez F, Callejas-Rubio JL, Rascon J, D’Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11(5):357–364

    Article  PubMed  CAS  Google Scholar 

  35. Dall’Era M, Wofsy D (2009) Systemic lupus erythematosus clinical trials—an interim analysis. Nat Rev Rheumatol 5(6):348–351

    Article  PubMed  Google Scholar 

  36. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(10):3077–3087

    Article  PubMed  CAS  Google Scholar 

  37. Wofsy D, Hillson JL, Diamond B (2012) Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 64(11):3660–3665

    Article  PubMed  CAS  Google Scholar 

  38. Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280–1286

    Article  PubMed  CAS  Google Scholar 

  39. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W (2013) Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 65(4):1011–1021

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  40. Merrill JT, Maciuca R, Ouyang W, McBride JM, Townsend MJ, Park E, Li J, Wei X, Morimoto A, Boismenu R, Davis JC Jr, Kennedy WP (2012) Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study. Arthritis Rheum 64(10):S1111, suppl

    Article  CAS  Google Scholar 

  41. Tcherepanova I, Curtis M, Sale M, Miesowicz F, Nicolette C (2012) Results of a randomized placebo controlled phase Ia study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis 71(Suppl 3):356

    Google Scholar 

  42. MedImmune LLC (2014) A study of the efficacy and safety of MEDI-546 in systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT01438489. Accessed 04 February 2014

  43. Lauwerys BR, Hachulla E, Spertini F, Lazaro E, Jorgensen C, Mariette X, Haelterman E, Grouard-Vogel G, Fanget B, Dhellin O, Vandepapeliere P, Houssiau FA (2013) Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 65(2):447–456

    Article  PubMed  CAS  Google Scholar 

  44. National Institute of A, Infectious D (2009) Etanercept for the treatment of lupus nephritis. http://ClinicalTrials.gov/show/NCT00447265. Accessed 04 February 2014

  45. Medical University of V, Hospital H, Medical University of G, Charite University BG, University of E-N, Heinrich-Heine University D, University Medical Centre G, Leiden University Medical C, Radboud U (2009) TNF blockade with remicade in active lupus nephritis WHO class V (TRIAL ). http://ClinicalTrials.gov/show/NCT00368264. Accessed 04 February 2014

  46. Pfizer (2013) A multiple dose study of PD-0360324 in patients with active cutaneous lupus erythematosus. http://ClinicalTrials.gov/show/NCT01470313. Accessed 04 February 2014

  47. Baxter Healthcare C (2013) Safety study of anti-macrophage migration inhibitory factor (anti-MIF) antibody in lupus nephritis. http://ClinicalTrials.gov/show/NCT01541670. Accessed 04 February 2014

  48. Novo N (2009) An investigation of NNC 0151-0000-0000 in subjects with systemic lupus erythematosus (SLE). http://ClinicalTrials.gov/show/NCT01018238. Accessed 04 February 2014

  49. Biogen I, Biogen Idec Australia Pty L, Biogen Idec Research L, Biogen Idec MAI (2016) Anti-tweak in lupus nephritis patients. http://ClinicalTrials.gov/show/NCT01499355. Accessed 04 February 2014

  50. Immunomedics I, Department of D (2015) Phase Ib study of SC milatuzumab in SLE. http://ClinicalTrials.gov/show/NCT01845740. Accessed 04 February 2014

  51. De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr (2012) Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol 11(10):1224–1226

    PubMed  Google Scholar 

  52. Invion I (2014) Double-blinded, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, and biochemical activity of intravenous Cpn10 administration in subjects with SLE. http://ClinicalTrials.gov/show/NCT01838694. Accessed 04 February 2014

  53. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368–2379

    Article  PubMed  CAS  Google Scholar 

  54. Wyeth (2008) Study of TRU-015 in subjects with membranous nephropathy secondary to systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT00479622. Accessed 04 February 2014

  55. Fleischmann R, Cohen S, Pardo P, Shaw M, Bhattacharya I, Sridharan S, Diehl A, Gourley I (2010) B cell depletion in subjects with controlled systemic lupus erythematosus (SLE) after intravenous or subcutaneous administration of SBI-087. Ann Rheum Dis 69(Suppl 3):550

    Google Scholar 

  56. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73(1):183–190

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  57. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, Houssiau F, Tak PP, Isenberg DA, Kelley L, Kilgallen B, Barry AN, Wegener WA, Goldenberg DM (2013) Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 52(7):1313–1322

    Article  CAS  Google Scholar 

  58. Eli L, Company (2014) A study of LY2127399 in patients with systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT01196091. Accessed 04 February 2014

  59. Furie R, Scheinberg M, Leon G, Ramiterre EB, Thomas M, Chu AD, Hislop C, Martin RS, Petri MA (2013) Effects of blisibimod, an inhibitor of B-cell activating factor, on markers of renal disease in patients with SLE. Ann Rheum Dis 72(Suppl 3):95

    Google Scholar 

  60. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14(1):R33

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  61. Serono EMD (2016) Efficacy and safety of atacicept in systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT01972568. Accessed 04 February 2014

  62. de Wilt LH, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FA (2013) Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol 85(3):363–372

    Article  PubMed  Google Scholar 

  63. The Rogosin I, Weill Medical College of Cornell U (2012) Velcade for proliferative lupus nephritis. http://ClinicalTrials.gov/show/NCT01169857. Accessed 04 February 2014

  64. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD (2008) Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 58(8):2470–2480

    Article  PubMed  CAS  Google Scholar 

  65. Teva Pharmaceutical I (2007) A study to evaluate the tolerability, safety and effectiveness of edratide in the treatment of lupus. http://ClinicalTrials.gov/show/NCT00203151. Accessed 04 February 2014

  66. National Institutes of Health Clinical C, National Institute of A, Musculoskeletal, Skin D (2014) Omalizumab for lupus. http://ClinicalTrials.gov/show/NCT01716312. Accessed 04 February 2014

  67. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(12):3251–3258

    Article  PubMed  CAS  Google Scholar 

  68. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48(3):719–727

    Article  PubMed  CAS  Google Scholar 

  69. Ucb I, Biogen I (2014) Safety study of CDP7657 in patients with systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT01764594. Accessed 04 February 2014

  70. National Institute of A, Infectious D, immune tolerance N treating systemic lupus erythematosus (SLE) patients with CTLA4-IgG4m (RG2077). http://ClinicalTrials.gov/show/NCT00094380. Accessed 04 February 2014

  71. Amgen (2016) Safety study of AMG 557 in subjects with lupus arthritis. http://ClinicalTrials.gov/show/NCT01683695. Accessed 04 February 2014

  72. Amgen (2013) Safety study of AMG 557 in subjects with subacute cutaneous lupus erythematosus. http://ClinicalTrials.gov/show/NCT01389895. Accessed 04 February 2014

  73. Amgen (2012) A study of AMG 557 in adults with systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT00774943. Accessed 04 February 2014

  74. MedImmune LLC, AstraZeneca (2012) A study of the safety and tolerability of MEDI-570 (experimental drug) in systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT01127321. Accessed 04 February 2014

  75. Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW Jr, Gordon R, Hsu B (2013) Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 65(10):2661–2671

    PubMed  CAS  Google Scholar 

  76. Pfizer (2014) Subcutaneous treatment in randomized subjects to evaluate safety and efficacy in generalized lupus erythematosus. http://ClinicalTrials.gov/show/NCT01405196. Accessed 04 February 2014

  77. National Institutes of Health Clinical C, National Institute of A, Musculoskeletal, Skin D (2007) Monoclonal antibody treatment for systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT00046774. Accessed 04 February 2014

  78. Novo N (2014) An investigation of safety and tolerability of NNC0114-0006 in subjects with systemic lupus erythematosus (SLE). http://ClinicalTrials.gov/show/NCT01689025. Accessed 04 February 2014

  79. Werth VP, Fiorentino D, Cohen SB, Fivenson D, Hansen C, Zoog S, Arnold G, Wang C, Boedigheimer M, Welcher A, Chung J, Sullivan B, Martin DA (2013) Phase I single-dose crossover study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of AMG 811 (anti-IFN-gamma) in subjects with discoid lupus erythematosus. Arthritis Rheum 65 (10 (suppl)):S682

  80. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J, Galanaud P, Emilie D (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43(8):1790–1800

    Article  PubMed  CAS  Google Scholar 

  81. Rigel P (2013) Safety and efficacy of topical R333 in patients with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) lesions. http://ClinicalTrials.gov/show/NCT01597050. Accessed 04 February 2014

  82. Rigel P (2009) Efficacy and safety study of R935788 tablets to treat systemic lupus erythematosus. http://ClinicalTrials.gov/show/NCT00752999. Accessed 04 February 2014

  83. GlaxoSmithKline (2015) An adaptive phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184. http://ClinicalTrials.gov/show/NCT01777256. Accessed 04 February 2014

  84. Celgene C (2012) A research study to assess if CC-930 is safe in treating subjects with discoid lupus erythematosus. http://ClinicalTrials.gov/show/NCT01466725. Accessed 04 February 2014

  85. Jayne D, Appel G, Chan T, Barkay H, Weiss R, Wofsy D (2013) A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis 72(suppl 3):164

    Google Scholar 

  86. Bengtsson A, Sturfelt G, Rönnblon L, Gunnarsson L, Svenungsson E, Jacobsen S, Lood C, Sparre B, Wallén Öhman M, Tuvesson H, Leanderson T (2011) An exploratory study to evaluate changes in disease activity and biomarkers during treatment with ABR-215757 in patients with mild active systemic lupus erythematosus (SLE). Ann Rheum Dis 70(Suppl 3):316

    Google Scholar 

  87. Chi H (2011) Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci 32(1):16–24

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  88. Sun Y, Wang W, Shan B, Di J, Chen L, Ren L, Li W, Li DJ, Lin Y (2011) FTY720-induced conversion of conventional Foxp3–CD4+ T cells to Foxp3+ regulatory T cells in NOD mice. Am J Reprod Immunol 66(5):349–362

    Article  PubMed  CAS  Google Scholar 

  89. Novartis, Novartis P (2012) Safety and efficacy of KRP203 in subacute cutaneous lupus erythematosus. http://ClinicalTrials.gov/show/NCT01294774. Accessed 04 February 2014

  90. Monneaux F, Hoebeke J, Sordet C, Nonn C, Briand JP, Maillere B, Sibillia J, Muller S (2005) Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog. J Immunol 175(9):5839–5847

    Article  PubMed  CAS  Google Scholar 

  91. Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S (2013) Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 72(11):1830–1835

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  92. Usmani N, Goodfield M (2007) Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 143(7):873–877

    Article  PubMed  CAS  Google Scholar 

  93. The Cleveland C discoid lupus erythematosus of the scalp and a trial of biologic therapy with raptiva. http://ClinicalTrials.gov/show/NCT00308204. Accessed 04 February 2014

  94. AbbVie (2014) A study to evaluate the safety, tolerability and pharmacokinetics of ABT-199 in female patients with systemic lupus erythematosus (SLE). http://ClinicalTrials.gov/show/NCT01686555. Accessed 04 February 2014

  95. Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M, Marchesoni A, Mosca M, Pai S, Manger K, Schneider M, Nielsen H, van Vollenhoven R, Swaak T (2010) Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19(8):949–956

    Article  PubMed  CAS  Google Scholar 

  96. Urowitz MB, Feletar M, Bruce IN, Ibanez D, Gladman DD (2005) Prolonged remission in systemic lupus erythematosus. J Rheumatol 32(8):1467–1472

    PubMed  Google Scholar 

  97. Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcon GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C (2012) Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 64(1):132–137

    Article  CAS  Google Scholar 

  98. National Institutes of Health (2014) Accelerating medicines partnership. http://www.nih.gov/science/amp/index.htm. Accessed 04 February 2014

Download references

Disclosures

None

Author information

Authors and Affiliations

  1. Servicio de Reumatología, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Perú

    Manuel F. Ugarte-Gil

  2. Universidad Científica del Sur, Lima, Perú

    Manuel F. Ugarte-Gil

  3. Department of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA

    Graciela S Alarcón

  4. Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Perú

    Graciela S Alarcón

Authors
  1. Manuel F. Ugarte-Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graciela S Alarcón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel F. Ugarte-Gil.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ugarte-Gil, M.F., Alarcón, G.S. Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol 33, 441–450 (2014). https://doi.org/10.1007/s10067-014-2531-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-014-2531-4

Keywords

Search

Navigation